Suven Life Sciences on Wednesday said it had been granted a product patent each by China and Eurasia corresponding to a new chemical entity (NCE) for the treatment of disorders associated with neurodegenerative diseases. These patents are valid till 2034, the company said in a BSE filing.
from The Pioneer - business https://ift.tt/2PizpMI
via
0 Comments